Dr Reddy's Laboratories Ltd, India's second-largest drugmaker by sales, said it expects no impact from a recent government notice that said the company is selling a high blood pressure drug that lacks the pricing regulator's approval. India's drug pricing regulator, the National Pharmaceutical Pricing Authority (NPPA), issued a show-cause notice to dozens of Indian and foreign drugmakers, who according to them, were selling medicines without NPPA approval on pricing. Calling it a violation of the country's drugs law, the agency has sought an explanation from these ...
Dr Reddy's sees no impact from pricing regulator notice
NPPA has issued a show-cause notice to dozens of Indian and foreign drugmakers